DJIA 17,849.49 21.74 0.12%
NASDAQ 4,796.79 9.48 0.20%
S&P 500 2,069.66 -3.17 -0.15%
market minute promo

Sanofi (ADR) (NYSE: SNY)



company name or ticker
Company Photos
(Click to zoom)

Alnylam Pharmaceuticals Staying Ridiculously Busy

VIVUS Posts Narrower-than-Expected Q3 Loss, Revenues Up - Analyst Blog

All Eyes on ISIS Pharmaceuticals, Inc.'s Pipeline

Isis has an approved drug, but earnings should be all about the pipeline of 32 drugs.

Regeneron Plunges In What Barron's Calls A Significant Disappointment: My Analysis

Alnylam Pharmaceuticals, Inc. Has This Ratio Right

Alnylam's third-quarter earnings call was all about the pipeline data.

Biotech Stock Roundup: Regeneron's Eylea Stumbles, Geron Up on Lifting of Clinical Hold - Analyst Bl

Biotech Stock Roundup: Regeneron's Eylea Stumbles, Geron Up on Lifting of Clinical Hold - Analyst Blog

Momenta Pharmaceuticals, Inc. Pushes Forward

With just $4.7 million from sales of enoxaparin in the third quarter, investors have to be focused on the pipeline.

What We Learned From The MannKind 3rd Quarter Conference Call

Regeneron Q3 Earnings Up Y/Y, Narrows Eylea Guidance - Analyst Blog

Regeneron Pharmaceuticals Inc. Earnings: Eylea's Roller-Coaster Ride

Regeneron Pharmaceuticals guides for 2014 U.S. Eylea sales toward the low end of previous guidance, causing shares to slip.
See More Articles...